Stéphanie Gaillard

5.2k total citations · 2 hit papers
103 papers, 3.2k citations indexed

About

Stéphanie Gaillard is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Stéphanie Gaillard has authored 103 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 41 papers in Reproductive Medicine and 29 papers in Molecular Biology. Recurrent topics in Stéphanie Gaillard's work include Ovarian cancer diagnosis and treatment (41 papers), Endometrial and Cervical Cancer Treatments (22 papers) and PARP inhibition in cancer therapy (13 papers). Stéphanie Gaillard is often cited by papers focused on Ovarian cancer diagnosis and treatment (41 papers), Endometrial and Cervical Cancer Treatments (22 papers) and PARP inhibition in cancer therapy (13 papers). Stéphanie Gaillard collaborates with scholars based in United States, United Kingdom and Japan. Stéphanie Gaillard's co-authors include Patrick J. Murphy, Tso-Pang Yao, William B. Pratt, June‐Tai Wu, David O. Toft, Christopher V. Nicchitta, Xuan Zhao, Minoru Yoshida, Jeffrey J. Kovacs and Donald P. McDonnell and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stéphanie Gaillard

97 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor

2005 936 citations Stéphanie Gaillard et al. profile →
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update

2025 15 citations Stéphanie Gaillard, Christina Lacchetti et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Stéphanie Gaillard

Since Specialization

Citations

This map shows the geographic impact of Stéphanie Gaillard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Gaillard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Gaillard more than expected).

Fields of papers citing papers by Stéphanie Gaillard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Gaillard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Gaillard. The network helps show where Stéphanie Gaillard may publish in the future.

Co-authorship network of co-authors of Stéphanie Gaillard

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Gaillard. A scholar is included among the top collaborators of Stéphanie Gaillard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Gaillard. Stéphanie Gaillard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibition of Glutamine Metabolism Attenuates Tumor Progression Through Remodeling of the Macrophage Immune Microenvironment 2025 ·Advanced Biology ·(unknown), (unknown), (unknown), Jiawei Fan, Tien-Chin Chang, Yao Shen, Jinming Yang, Barbara S. Slusher, Ie−Ming Shih, Stéphanie Gaillard, Tian‐Li Wang	2
2	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update 2025 ·Obstetrical & Gynecological Survey ·Stéphanie Gaillard, Christina Lacchetti, Deborah K. Armstrong, William A. Cliby, Mitchell I. Edelson, Agustin A. García, (unknown), Gregory M. Gressel, Jamie Lesnock, Larissa A. Meyer, Kathleen N. Moore, Roisin E. O’Cearbhaill, Alexander Olawaiye, (unknown), Dee Sparacio, Willemien J. van Driel, William P. Tew	0
3	FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma 2025 ·Journal of Gynecologic Oncology ·(unknown), Marta Llauradó Fernández, (unknown), (unknown), Linda S. Cook, (unknown), (unknown), Stéphanie Gaillard, (unknown), Amy Dawson, (unknown), (unknown), Nelson K.Y. Wong, (unknown), Anna V. Tinker, Mark Carey, Martin Köbel	3
4	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Clinical Insights 2025 ·JCO Oncology Practice ·William P. Tew, Christina Lacchetti, Stéphanie Gaillard	1
5	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update breakdown → 2025 ·Journal of Clinical Oncology ·Stéphanie Gaillard, Christina Lacchetti, Deborah K. Armstrong, William A. Cliby, Mitchell I. Edelson, Agustin A. García, (unknown), Gregory M. Gressel, Jamie Lesnock, Larissa A. Meyer, Kathleen N. Moore, Roisin E. O’Cearbhaill, Alexander Olawaiye, (unknown), Dee Sparacio, Willemien J. van Driel, William P. Tew	15
6	Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication 2024 ·Cancer Research ·(unknown), (unknown), Juliane Liberto, Stéphanie Gaillard, Tian‐Li Wang, Ie−Ming Shih	2
7	Characterization of ESR1 mutations in endometrial and ovarian cancers. 2024 ·Journal of Clinical Oncology ·Stéphanie Gaillard, (unknown), Sachin Kumar Deshmukh, Utthara Nayar, Joanne Xiu, (unknown), (unknown), George W. Sledge, Thomas J. Herzog, Premal H. Thaker, Sharon Wu	1
8	606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors 2024 ·Annals of Oncology ·Funda Meric‐Bernstam, Yoichi Naito, Stéphanie Gaillard, (unknown), Vincent Chung, Andrew A. Davis, Theresa A. Proia, (unknown), Manjusha Kulkarni, (unknown), Neil R. Miller, Nadia Luheshi, Andreea Varga, D-Y. Oh, Linda Mileshkin	7
9	Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer 2023 ·Cancer Research Communications ·Channing J. Paller, Lin Wang, Wei Fu, Rajendra Kumar, Jennifer N. Durham, Nilofer S. Azad, Daniel A. Laheru, Ilene Browner, Sushant K. Kachhap, (unknown), Thomas Odeny, Deborah K. Armstrong, Christian F. Meyer, Stéphanie Gaillard, Julie R. Brahmer, (unknown), Hao Wang, Luis A. Díaz	7
10	C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer 2023 ·Clinical Cancer Research ·Stephanie L. Wethington, Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan, Drew A. Torigian, (unknown), Simon A. Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie−Ming Shih, Eric J. Brown, Wei‐Ting Hwang, Deborah K. Armstrong, Stéphanie Gaillard, Robert Giuntoli, Fiona Simpkins	40
11	Temozolomide Sensitizes ARID1A -Mutated Cancers to PARP Inhibitors 2023 ·Cancer Research ·(unknown), (unknown), Ellen Tully, Peng Huang, (unknown), Philipp Oberdoerffer, Stéphanie Gaillard, Ie−Ming Shih, Tian‐Li Wang	12
12	Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC) 2022 ·Genes & Diseases ·Jiaxin Hong, Yao Shen, Chih‐Yi Hsu, Peng Huang, (unknown), Edward Gabrielson, Ie−Ming Shih, Stéphanie Gaillard, Tian‐Li Wang	12
13	Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy 2021 ·iScience ·Yao Shen, Jin Gyoung Jung, Geoffrey D. Shimberg, Fang‐Chi Hsu, Yohan Suryo Rahmanto, Stéphanie Gaillard, Jiaxin Hong, Jürgen Bosch, Ie−Ming Shih, Chi‐Mu Chuang, Tian‐Li Wang	17
14	A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening 2021 ·Laboratory Investigation ·Youngran Park, (unknown), (unknown), Ryoichi Asaka, Wenjing Shen, Yeh Wang, Wei‐Hung Jung, (unknown), (unknown), Yun Chen, Vamsi Parimi, Stéphanie Gaillard, Ie‐Ming Shih, Tian‐Li Wang	17
15	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers 2020 ·Cancer Research ·Yao Shen, Jiaxin Hong, (unknown), Shiho Asaka, Fang‐Chi Hsu, Yohan Suryo Rahmanto, (unknown), (unknown), Ting‐Tai Yen, (unknown), Cissy Zhang, Nabeel Attarwala, Angelo M. De Marzo, Ben Davidson, Chi-Mu Chuang, Xi Chen, Stéphanie Gaillard, Anne Le, Ie‐Ming Shih, Tian‐Li Wang	60
16	Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report 2020 ·Gynecologic Oncology Reports ·(unknown), (unknown), Maryam Shahi, Russell Vang, Stéphanie Gaillard, Thomas J. Smith, Amanda N. Fader	2
17	PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model 2020 ·Cancer Immunology Immunotherapy ·Shiwen Peng, Marietta Tan, Yen-Der Li, (unknown), Emily Farmer, Louise Ferrall, Stéphanie Gaillard, Richard B.S. Roden, Chien‐Fu Hung, T.‐C. Wu	24
18	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy 2019 ·Clinical Cancer Research ·Youngran Park, M. Herman Chui, Yohan Suryo Rahmanto, (unknown), Raghavendra A. Shamanna, Marina A. Bellani, Stéphanie Gaillard, A. Ayhan, Akila Viswanathan, Michael M. Seidman, Sonia Franco, Anthony K. L. Leung, Vilhelm A. Bohr, Ie‐Ming Shih, Tian‐Li Wang	95
19	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer 2019 ·International Journal of Gynecological Pathology ·Ting‐Tai Yen, Tian‐Li Wang, Amanda N. Fader, Ie‐Ming Shih, Stéphanie Gaillard	88
20	Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy 2011 ·Journal of Clinical Virology ·Stéphanie Gaillard, Jason B. Dinoso, (unknown), Amy E. DeZern, Karen A. O’Connell, Adam M. Spivak, Karla Alwood, Christine M. Durand, Richard F. Ambinder, Joel N. Blankson	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact